Search

Displaying results 1831 - 1840 of 10000 in total
  1. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell

    Synonyms: 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
  2. Drug

    Carbocisteine

    go.drugbank.com/drugs/DB04339
    ApprovedInvestigational

    [A230993] Carbocisteine is currently not FDA or Health Canada approved, but is approved for use in Asia, Europe, and South America. … reported by physicians in France and Italy.

    Synonyms: L-carbocysteine, S-carboxymethyl-L-cysteineProducts: MUCOSIS 50 MG/ML ŞURUP, 100 ML, MUKO-S 250 MG/5 ML ŞURUP, 100 ML
  3. Drug

    Linoleic acid

    go.drugbank.com/drugs/DB14104
    Approved

    Mixtures: Borage Oil Capsules, Borage Oil Capsules
  4. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]

    Products: Gerodaza 25 mg/ml-Pulver zur Herstellung einer Injektionssuspension, Azacitidin STADA 25 mg/ml Pulver zur Herstellung einer Injektionssuspension
  5. Drug

    N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)

    go.drugbank.com/drugs/DB11202
    Approved

    It is found in sanitizing solutions or soaps as an active ingredient due to its antimicrobial properties. … Employed in a great variety of cleaning agents and sanitizing agents, it possesses relatively broad gram-positive and gram-negative antibacterial activities and relatively little chance for systemic absorption

    Mixtures: Med-I-San, Med-I-San
  6. Drug

    Trifluridine

    go.drugbank.com/drugs/DB00432
    ApprovedInvestigational

    It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. … Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine] [A35271].

    Products: THILO %1 GÖZ DAMLASI, 5 ML
  7. Drug

    Technetium Tc-99m nofetumomab merpentan

    go.drugbank.com/drugs/DB09336
    ApprovedWithdrawn

    It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082] … [A32115] The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues.

  8. Drug

    Nitrogen

    go.drugbank.com/drugs/DB09152
    ApprovedInvestigationalVet approved

    Nitrogen is a chemical element with symbol N and atomic number 7. At room temperature, it is a transparent, odorless diatomic gas. … Also, nitrogen is very famous component in fertilizers and energy-stores.

  9. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L51998,A264878] This novel mechanism of action is effective even in the presence of inhibitors towards factors VIII or IX, as it essentially skips the intrinsic pathway in which factors VIII and IX participate … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting

  10. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy